Agenus Inc (NASDAQ: AGEN) stock jumped 7.57% on Monday to $0.74 against a previous-day closing price of $0.69. With 10.83 million shares changed hands, the volume of the stock remained heavier than its average volume of 5.74 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.7549 whereas the lowest price it dropped to was $0.6873. The 52-week range on AGEN shows that it touched its highest point at $3.25 and its lowest point at $0.61 during that stretch. It currently has a 1-year price target of $6.50. Beta for the stock currently stands at 1.30.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AGEN was up-trending over the past week, with a rise of 18.18%, but this was down by -17.00% over a month. Three-month performance dropped to -50.85% while six-month performance fell -50.19%. The stock lost -76.14% in the past year, while it has lost -68.49% so far this year. A look at the trailing 12-month EPS for AGEN yields -0.82 with Next year EPS estimates of -0.39. For the next quarter, that number is -0.06. This implies an EPS growth rate of 16.91% for this year and 38.36% for next year.
Float and Shares Shorts:
At present, 381.50 million AGEN shares are outstanding with a float of 363.55 million shares on hand for trading. On Oct 30, 2023, short shares totaled 34.18 million, which was 9.00% higher than short shares on Sep 28, 2023. In addition to Dr. Garo H. Armen Ph.D. as the firm’s Founder, Executive Chairman & CEO, Ms. Christine M. Klaskin serves as its VP of Finance, Principal Financial Officer & Principal Accounting Officer.
Institutional Ownership:
Through their ownership of 60.95% of AGEN’s outstanding shares, institutional investors have majority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AGEN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With AGEN analysts setting a high price target of $8.00 and a low target of $6.00, the average target price over the next 12 months is $6.50. Based on these targets, AGEN could surge 981.08% to reach the target high and rise by 710.81% to reach the target low. Reaching the average price target will result in a growth of 778.38% from current levels.
Summary of Insider Activity:
Insiders traded AGEN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.
